---
title: CRISPR Therapeutics (CRSP) — stock overview: intrinsic value, grades and financials
canonical: https://sweetvaluelab.com/stocks/crsp
ticker: CRSP
as_of: 2026-11-02
sector: Healthcare
industry: Biotechnology
---
# CRISPR Therapeutics (CRSP)

CRISPR Therapeutics (CRSP) holds a Quant grade of D (model v1, Oct 30), on a scale from S, the best, to D. It closed at $51.42 on Oct 30, 2026, overvalued by 158% vs model: EV/Revenue · peers puts it at $19.90 a share. The median analyst target is $60.00 from 9 firms.

In Q2 FY2026, the latest quarter on file, revenue grew 1041% on a year earlier to $10.2M, with an operating margin of −1127.6%. Over the twelve months to Q2 FY2026, free cash flow was -$373.8M.

Insiders sold $4.9M and made no open-market purchases over the last 90 days. The latest filing is an 8-K (current report), filed Oct 19.

The valuation in full, model by model: https://sweetvaluelab.com/stocks/crsp/valuation.

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $51.42 (Oct 30, 2026) |
| Model value (from its peers' median EV/Revenue) | $19.90 |
| Price vs model | overvalued by 158% vs model |
| Range of that model | $19.85 – $20.32 |
| Market value | $5.0B |
| P/E (fiscal 2025) | — |
| Net margin (fiscal 2025) | −16569.8% |
| Free cash flow (fiscal 2025) | -$345.9M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 1.76 |
| Cost of capital (WACC) | 10.89% |
| Business classification | Loss-Making (Revenue declining (~-90% recent), Decelerated from ~37% 5y CAGR, Currently unprofitable, Highly cyclical earnings, Negative free cash flow) |

## The last eight quarters

| Quarter | Revenue | Change on a year earlier | Operating margin |
| --- | ---: | ---: | ---: |
| Q3 FY2024 | $602,000 | — | −18294.0% |
| Q4 FY2024 | $35.0M | — | −184.5% |
| Q1 FY2025 | $865,000 | — | −17158.8% |
| Q2 FY2025 | $892,000 | — | −14918.3% |
| Q3 FY2025 | $889,000 | +47.7% | −14854.8% |
| Q4 FY2025 | $864,000 | −97.5% | −17912.5% |
| Q1 FY2026 | $1.5M | +68.6% | −8933.3% |
| Q2 FY2026 | $10.2M | +1041.4% | −1127.6% |

Twelve months to Q2 FY2026, against the twelve before:

| Line | Latest | Year before |
| --- | ---: | ---: |
| Revenue | $13.4M | $37.4M |
| Operating income | -$531.9M | -$456.2M |
| Net income | -$451.1M | -$467.8M |
| Free cash flow | -$373.8M | -$325.6M |
| Diluted EPS | -$4.71 | -$5.43 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Nov 2, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $0.00 | $0.00 | $0.00 |
| DCF · Perpetuity growth · 10y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 5y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 10y | cross check | $0.00 | $0.00 | $0.00 |
| EV/EBITDA · peers | cross check | $0.00 | $0.00 | $0.00 |
| EV/Revenue · peers | cross check | $19.90 | $19.85 | $20.32 |
| Earnings power value | cross check | $0.00 | $0.00 | $0.00 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Wall Street analysts

The median of each covering firm's latest price target is $60.00, from 9 firms — the analysts' figure, quoted, and not part of the model value above. Each firm's latest target, the current grades, the grade changes and the consensus revenue and EPS estimates: https://sweetvaluelab.com/stocks/crsp/analysts (Markdown: https://sweetvaluelab.com/stocks/crsp/analysts.md).

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 7 open-market sales ($4.9M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 26, 2026 | Silver Andrew Jacob | Chief Financial Officer | Grant / award | 9,000 | $0 |
| Oct 26, 2026 | Silver Andrew Jacob | Chief Financial Officer | Grant / award | 18,000 | $0 |
| Oct 26, 2026 | KASINGER JAMES R. | General Counsel and Secretary | Grant / award | 18,000 | $0 |
| Oct 26, 2026 | KASINGER JAMES R. | General Counsel and Secretary | Grant / award | 9,000 | $0 |
| Oct 26, 2026 | Kulkarni Samarth | Chief Executive Officer | Grant / award | 57,500 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 19, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm |
| Aug 3, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm |
| Aug 3, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm |
| Jun 5, 2026 | S-8 | Employee stock plan registration | https://www.sec.gov/Archives/edgar/data/1674416/000119312526258473/crsp-20260605.htm |
| Jun 4, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 5.03 Amendment to Articles/Bylaws; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/crsp-20260604.htm |

## About

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells…

---

Source: https://sweetvaluelab.com/stocks/crsp (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.